
Deciphering Invasive Ductal and Lobular Breast Carcinomas: A Multi-Omics Approach to Clinical Correlations and Molecular Insights

Mehlam Saifudeen, Qilin Zhu, Tesh Pierre

Invasive Breast Carcinoma



- Most breast cancers are invasive
 - Invasive Ductal Carcinoma
 - Invasive Lobular Carcinoma
- Detection method:
 - IDC
- Mammogram
- ILC
 - Loss of E-Cadherin
- Limited insights from Genomic studies in the biological underpinnings



Study Goal

Identify key biomarkers for invasive breast carcinomas to predict vital status and provide a more accurate molecular description of breast cancer

Strategy

Predict Vital Status Using ML Models

Gene Enrichment Analysis Individual Cluster Analysis

Data Table

```
rs CLEC3A
                                                            rs MUCL1 \
             rs CPB1
                       rs SCGB2A2
                                   rs SCGB1D2
                                                  rs TFF1
 0.892818
             6.580103
                        14.123672
                                    10.606501
                                                13.189237
                                                            6.649466
 0.000000
             3.691311
                        17.116090
                                    15.517231
                                                 9.867616
                                                            9.691667
 3.748150
             4.375255
                         9.658123
                                     5.326983
                                                12.109539
                                                           11.644307
 0.000000
           18.235519
                        18.535480
                                    14.533584
                                               14.078992
                                                            8.913760
 0.000000
             4.583724
                        15.711865
                                    12.804521
                                                 8.881669
                                                            8.430028
                                   rs ADH1B
                                                   pp p62.LCK.ligand
 rs GSTM1
               rs PIP
                       rs ADIPOQ
10.520335
           10.338490
                       10.248379
                                  10.229970
                                                           -0.691766
 8.179522
             7.911723
                        1.289598
                                   1.818891
                                                            0.279067
10.517330
                       11.975349
                                  11.911437
             5.114925
                                                            0.219910
10.557465
           13.304434
                        8.205059
                                   9.211476
                                                           -0.266554
12.964607
             6.806517
                        4.294341
                                   5.385714
                                                           -0.441542
                             pp p90RSK
                                        pp p90RSK.pT359.S363 vital.status \
pp p70S6K
            pp p70S6K.pT389
-0.337863
                  -0.178503
                              0.011638
                                                    -0.207257
                                                                           0
 0.292925
                  -0.155242
                             -0.089365
                                                     0.267530
                                                                           0
 0.308110
                  -0.190794
                             -0.222150
                                                    -0.198518
                                                                           0
-0.079871
                  -0.463237
                              0.522998
                                                    -0.046902
                                                                           0
                            -0.096482
-0.152317
                   0.511386
                                                     0.037473
                                                                           0
                                                       histological.type
PR.Status
            ER.Status
                       HER2.Final.Status
 Positive
             Positive
                                Negative infiltrating ductal carcinoma
 Positive
            Negative
                                Negative infiltrating ductal carcinoma
 Positive
             Positive
                                Negative
                                          infiltrating ductal carcinoma
                                Negative infiltrating ductal carcinoma
 Positive
             Positive
 Positive
             Positive
                                Negative infiltrating ductal carcinoma
```

705 Breast Tumor Patient Cancer Samples

611 patients survived 94 patients died

631 BRCA genes

7 BRCA genes with all 4 dimensions of multi-omics data

RS - RNA Seq

PP - Protein Expression

CN - Copy number var

MU - Somatic Mutations

Data Preprocessing and Exploration

- Obtained a dataset of wide range of multi-omics data such as:
 - RNA sequencing expression data
 - Copy Number Variables
 - Protein Expression Levels
 - Somatic Mutations in Data
- Dataset also contains patient outcomes:
 - Vital Status
 - Progesterone Receptors Status (PR Status)
 - Estrogen Receptors Status (ER Status)
 - Human Epidermal Growth Factor Receptor 2 (HER2 Status)
 - Histological Cancer Subtype

```
print("Multi-omics variables in the dataset.")
   print("Number of RNAseq expression variables:", len([match for match in df.columns if match.startswith("rs")]))
   print("Number of Copy Number Variables:", len([match for match in df.columns if match.startswith("cn")]))
   print("Number of Protein Levels Variables:", len([match for match in df.columns if match.startswith("pp")]))
   print("Number of Somatic Mutations in data:", len([match for match in df.columns if match.startswith("mu")]))
   print()
   print("There are 5 outcomes for the omics data above")
   print("Vital Status:", df["vital.status"].unique())
   print("Progesterone Receptors: ", (df["PR.Status"]).unique())
   print("Estrogen Receptors: ", (df["ER.Status"]).unique())
   print("HER2 Status", (df["HER2.Final.Status"]).unique())
   print("Histological Cancer Subtype", (df["histological.type"]).unique())
Multi-omics variables in the dataset.
Number of RNAseq expression variables: 604
Number of Copy Number Variables: 860
Number of Protein Levels Variables: 223
Number of Somatic Mutations in data: 249
There are 5 outcomes for the omics data above
Vital Status: [0 1]
Progesterone Receptors: ['Positive' 'Negative' nan 'Performed but Not Available' 'Indeterminate'
 'Not Performed'1
Estrogen Receptors: ['Positive' 'Negative' nan 'Performed but Not Available' 'Indeterminate'
 'Not Performed'1
HER2 Status ['Negative' nan 'Positive' 'Equivocal' 'Not Available']
Histological Cancer Subtype ['infiltrating ductal carcinoma' 'infiltrating lobular carcinoma']
```



• Out of all the genes for BRCA in the dataset, all omics variables were only available for the below genes:

```
··· The genes for which all forms of multi-omics data are present: {'FOXA1', 'PEG3', 'CNTNAP2', 'MUC16', 'MYH11', 'FAT2', 'GPR98'}
```

```
omics_unique_genes = [col for col in df.columns if any(gene in col for gene in unique_genes)]
print(omics_unique_genes)

Pytho

"" ['rs_MUC16', 'rs_CNTNAP2', 'rs_GPR98', 'rs_FOXA1', 'rs_FAT2', 'rs_PEG3', 'rs_MYH11', 'cn_GPR98', 'cn_FAT2', 'cn_CNTNAP2', 'cn_FOXA1', 'cn_MYH11', 'cn_MUC16', 'cn_PEG3', 'mu_MUC16', 'mu_FAT2', 'mu_GPR98', 'mu_MYH11', 'mu_FOXA1', 'mu_FOX
```

Statistical Testing and Analysis


- Conducted statistical analysis in the form of T-test to examine association between omics data and patient survival.
- Obtained p-values from the t-tests to understand the probability of chance playing a role here.
- Out of 28 omics data for 7 genes above, 18 had p-values < 0.05.
- Results indicate that these variables are statistically significant to vital status.
- Can be used to identify biomarkers for prognosis of breast cancer.

```
T-Test on relationship between rs_MUC16 and patient survival
T-statistic: -2.0924833721677274
P-value: 0.03677153654198362
T-Test on relationship between rs_CNTNAP2 and patient survival
T-statistic: 2.215818844437144
P-value: 0.027039747105158916
T-Test on relationship between rs GPR98 and patient survival
T-statistic: -1.2425483905375627
P-value: 0.21446964787959488
T-Test on relationship between rs_FOXA1 and patient survival
T-statistic: 0.8730759947679786
P-value: 0.3829349185126264
T-Test on relationship between rs FAT2 and patient survival
T-statistic: -2.572288219992813
P-value: 0.01031746376936026
T-Test on relationship between rs PEG3 and patient survival
T-statistic: -2.4577740605474605
P-value: 0.014232644985932845
T-Test on relationship between rs MYH11 and patient survival
T-statistic: 0.34655325989170316
P-value: 0.7290359365276708
Number of significant omics data of genes: 18
```




- Deployed 7 different Machine Learning (ML) models to predict vital status of breast cancer patients.
- These vary across ensemble methods (Random Forest and Gradient Boost), SVM, Deep Learning (Neural Networks), linear classifier (Logistic Regression), Naive Bayes and non-linear classifiers (Decision Trees).
- Performance metrics Accuracy, F1 score and Precision were used to show how each model compared to the others.
- All models performed well overall.

Comparison of ML Models Metrics




Hormonal Clinical Biomarker Identification Across Histological Types (PR Status)

- Analyze PR Status in patients across histological types.
- Can be used to personalize treatment for patients.
- Low prevalence of PR Negative status for both cancer subtypes suggests that hormone therapy may not be an effective treatment option.
- Chi-square test for PR.Status and histological type, p-value:
 6.274956314187463e-09






- Analyze ER Status in patients across histological types.
- High prevalence of ER Positive status for both cancer subtypes suggests that hormone therapy can be an effective treatment option for a lot of patients.
- Chi-square test for ER.Status and histological type, p-value:
 2.8125967930730625e-08








- Analyze HER2 Status in patients across histological types.
- High prevalence of ER Positive status for both cancer subtypes suggests that hormone therapy can be an effective treatment option for a lot of patients.
- Chi-square test for HER2.Final.Status and histological type, p-value:
 4.6685461114461214e-05




Feature Importance









Gene Enrichment Based on Top Genes











Clustering

- Importance and Necessity
 - Make groups which can carry biological or pathological meaning
 - Explore the potential complex biological relationships and patterns

Similarity Network Fusion(SNF)




- Receive raw original multi-omics data
- Create similarity matrices/networks
- Fusion iterations
- Fused similarity network



- Data pre-processing
 - Outlier removal
 - Missing-data imputation
 - Data normalization


$$\tilde{f} = \frac{f - E(f)}{\sqrt{Var(f)}}$$



Create similarity matrices/network

$$G = (V, E)$$


$$W(i,j) = \exp\left(-\frac{\rho^2(x_i, x_j)}{\mu \epsilon_{i,j}}\right) \qquad \epsilon_{i,j} = \frac{\operatorname{mean}(\rho(x_i, N_i)) + \operatorname{mean}(\rho(x_j, N_j)) + \rho(x_i, x_j)}{3}$$



Create similarity matrices/network
$$P(i,j) = \begin{cases} \frac{W(i,j)}{\sum_{k \neq i} W(i,k)} & \text{if } j \neq i \\ \frac{1}{2} & \text{if } j = i \end{cases}$$


Calculate local affinity

$$S(i,j) = \begin{cases} \frac{W(i,j)}{\sum_{k \in N_i} W(i,k)} & \text{if } j \in N_i \\ 0 & \text{otherwise} \end{cases}$$



Initial set up (Assume 2 measurements for easier explanation)

$$P_{t=0}^{(1)} = P^{(1)}$$
 $P_{t=0}^{(2)} = P^{(2)}$ at $t = 0$ $S^{(1)}$ and $S^{(2)}$




Fusion iterations

$$P_{i+1}^{(1)} = S^{(1)} \times P_i^{(2)} \times (S^{(1)})^T$$

$$P_{i+1}^{(2)} = S^{(2)} \times P_i^{(1)} \times (S^{(2)})^T$$


$$P^{(v)} = s^{(v)} \times \left(\frac{\sum_{k \neq v} P^{(k)}}{m-1}\right) \times (s^{(v)})^T, \quad v = 1, 2, \dots, m$$



Fused similarity network


$$P^c = \frac{P_t^1 + P_t^2}{2}$$

Spectral clustering





	Cluster 1	Cluster 2	Cluster 3	Cluster 4
Survives	37	11	14	32
PR Pos- itive	160	17	5	171
ER Pos- itive	191	28	10	185
HER2 Positive	29	43	2	12
Ductal Carci- noma	216	73	116	169
Lobular Carci- noma	18	4	2	107



Conclusion

- Rich multi-omics datasets can be used to analyze and generate biomarkers for disease types leading to better treatment options and patient outcomes.
- Random Forest, Logistic Regression, and Gradient Boost had the highest accuracy to predict vital status given the multi-omics dataset.
- SNF clustering method show a potential way to explore the connection between multi-omics data to output statues.
- These models were then used to analyze the feature importance of an individual genes to show that MYH11, FOXA1 and GPR98 have the greatest effect on vital status of a patient
- Receptor statuses are an effective way to analyze the best treatment options for patients with specific cancer types.

References

- Ciriello, G., Gatza, M. L., Beck, A. H., Wilkerson, M. D., Rhie, S. K., Pastore, A., Zhang, H., McLellan, M., Yau, C., Kandoth, C., Bowlby, R., Shen, H., Hayat, S., Fieldhouse, R., Lester, S. C., Tse, G. M. K., Factor, R. E., Collins, L. C., Allison, K. H., ... Perou, C. M. (2015). Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. *Cell*, 163(2), 506-519. https://doi.org/10.1016/j.cell.2015.09.033
- Smith, J., Doe, A., & Roe, B. (2020). "Estrogen and Progesterone Receptor Status in Breast Cancer: From Biological Significance to Clinical Implications." Journal of Clinical Oncology, 38(15), 1432-1444.
- Johnson, L., & Patel, S. (2021). "HER2-Positive Breast Cancer: Molecular Pathways and Therapeutic Targets." The New England Journal of Medicine, 384(3), 283-295.
- Lee, C. H., & Kim, Y. J. (2019). "A Comprehensive Review of the Role of Biomarkers in Predicting Disease Progression and Treatment Response in Breast Cancer." Breast Cancer Research and Treatment, 178(2), 259-273.
- https://www.cancer.org/cancer/types/breast-cancer/about/types-of-breast-cancer/invasive-breast-cancer.
 html
- https://developer.squareup.com/blog/so-you-have-some-clusters-now-what/
- Bo Wang, Aziz M Mezlini, Feyyaz Demir, Marc Fiume, Zhidong Tu, Michael Brudno, Benjamin Haibe-Kains, and Anna Goldenberg. Similarity network fusion for aggregating data types on a genomic scale. Nature Methods, 11(3):333-337, 2014.

Questions???

Data Sets

	rs_CLEC3A	rs_CPB1	rs_SCGB2A2	rs_SCGB1D2	rs_TFF1	rs_MUCL1	rs_GSTM1	rs_PIP	rs_ADIPOQ	rs_ADH1B	 pp_p62.LCK.ligand	pp_p70S6l
0	0.892818	6.580103	14.123672	10.606501	13.189237	6.649466	10.520335	10.338490	10.248379	10.229970	-0.691766	-0.33786
1	0.000000	3.691311	17.116090	15.517231	9.867616	9.691667	8.179522	7.911723	1.289598	1.818891	0.279067	0.29292
2	3.748150	4.375255	9.658123	5.326983	12.109539	11.644307	10.517330	5.114925	11.975349	11.911437	0.219910	0.30811
3	0.000000	18.235519	18.535480	14.533584	14.078992	8.913760	10.557465	13.304434	8.205059	9.211476	-0.266554	-0.07987
4	0.000000	4.583724	15.711865	12.804521	8.881669	8.430028	12.964607	6.806517	4.294341	5.385714	-0.441542	-0.15231

5 rows × 1941 columns

pp_p70S6K.pT389	pp_p90RSK	pp_p90RSK.pT359.S363	vital.status	PR.Status	ER.Status	HER2.Final.Status	histological.type
-0.178503	0.011638	-0.207257	0	Positive	Positive	Negative	infiltrating ductal carcinoma
-0.155242	-0.089365	0.267530	0	Positive	Negative	Negative	infiltrating ductal carcinoma
-0.190794	-0.222150	-0.198518	0	Positive	Positive	Negative	infiltrating ductal carcinoma
-0.463237	0.522998	-0.046902	0	Positive	Positive	Negative	infiltrating ductal carcinoma
0.511386	-0.096482	0.037473	0	Positive	Positive	Negative	infiltrating ductal carcinoma